ad image

Retinal

1 / 1
The Shift from Early- to Late-Phase Ophthalmology Retina Market in 2024: Proactive Planning for Late-Stage Clinical Success
Ophthalmology

The Shift from Early- to Late-Phase Ophthalmology Retina Market in 2024: Proactive Planning for Late-Stage Clinical Success

Tracey Roberts, MSHS; Jennifer Christiansen, Ph.D.; Debra Schaumberg, Sc.D., O.D., M.P.H.

PPD, part of Thermo Fisher Scientific

PAO-08-24-CL-05Sep 16, 2024
Pioneering Breakthroughs in Retinal Disease Treatment
Retinal Disease

Pioneering Breakthroughs in Retinal Disease Treatment

David Alvaro, Ph.D.; David Zacks, M.D., Ph.D.; David Esposito

Pharma's Almanac

PAO-12-23-CL-01Dec 14, 2023
Transformative Early and Patient-Centric Treatments for Retinal Diseases
Ophthalmic

Transformative Early and Patient-Centric Treatments for Retinal Diseases

David Alvaro, Ph.D.; Kerrie Brady

Pharma's Almanac

PAO-05-022-CL-06May 17, 2022
Targeting Retinal Diseases with an Ophthalmic Formulation of Bevacizumab
Ophthalmic Formulation

Targeting Retinal Diseases with an Ophthalmic Formulation of Bevacizumab

Larry Kenyon

Outlook Therapeutics

PAP-Q4-20-CL-018Dec 09, 2020
Innovative Therapies to Treat Rare and Underserved Eye Diseases
Ophthalmology

Innovative Therapies to Treat Rare and Underserved Eye Diseases

Shankar Musunuri, Ph.D.

Ocugen

PAP-Q4-19-CL-025Dec 06, 2019
Aldeyra Therapeutics

Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision

Aldeyra Therapeutics

PR-M01-19-NI-096Feb 01, 2019
ProtoKinetix
Retinal Cell Replacement Therapy

ProtoKinetix Enters into 3rd Phase of Retinal Cell Replacement Therapy Testing at UBC

ProtoKinetix

PR-M09-18-NI-001Sep 04, 2018
1 / 1